Skip to main content

Table 3 Vaccine efficacy to prevent HIV RNA rebound (phase II primary end point)

From: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

Tat Oyi 0 (n = 12) 11 µg (n = 12) 33 µg (n = 12) 99 µg (n = 10)
Medians (copies/ml) 12,921 20,706 442 9475
Total range 39–0.9 × 106 39–1.2 × 106 39–0.4 × 106 81–0.1 × 106
Log medians 4.1 4.3 2.6 4.0
p values*   0.38 0.07 0.50
  1. HIV RNA at M6 after cART interruption at M5
  2. p values were determined for each vaccine group versus placebo with a one sided Mann and Whitney test without adjustment. Undetectable viraemia (<40 copies/ml) were replaced by 39 (1.6 log) copies/ml